Skip to main content
Export Citation
Export CitationsAdd to FavoritesRecommend
Objective: Xanomeline and trospium chloride (formerly known as KarXT), a novel M1/M4 muscarinic receptor agonist, demonstrated efficacy across phase 2 and 3 trials as monotherapy for the treatment of inpatients with acute schizophrenia on the Positive and ...
article
Full Access
American Journal of PsychiatryReviews and Overviews27 June 2022

Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia

Schizophrenia remains a challenging disease to treat effectively with current antipsychotic medications due to their limited efficacy across the entire spectrum of core symptoms as well as their often burdensome side-effect profiles and poor tolerability. ... 

Please login to be able to save your searches and receive alerts for new content matching your search criteria.